The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria

Contributed by: Business Wire

Logo

Tags

Research

Genetics

Clinical Trials

Biotechnology

Other Health

Health

Pharmaceutical

General Health

Science

Forge Biologics

More Like This

Forge Biologics Announces the FUEL™ AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production

Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation

Forge Biologics Announces Publication in Human Gene Therapy on a Novel Finding That Changes a Fundamental Understanding of AAV Production

Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome

PR Newswire associated0

Ajinomoto Bio-Pharma Services and Gene Tools Announce Collaboration to Expand Access to PMO Therapeutics